Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company based in Vancouver, British Columbia. The company specializes in developing and commercializing photodisinfection-based antimicrobial therapies aimed at preventing and treating a wide range of infections, including those caused by multidrug-resistant pathogens. Their core technology, photodisinfection, utilizes a patented light-based platform that activates a photosensitive agent to produce an oxidative burst, effectively destroying bacteria, viruses, and fungi without harming human tissue. Ondine's lead product, Steriwave™, is a medical device designed for rapid nasal decolonization, significantly reducing healthcare-associated infections by targeting common nasal pathogens. The device has been successfully implemented in Canadian hospitals, contributing to a notable reduction in surgical site infections. In addition to Steriwave™, Ondine has a pipeline of investigational anti-infective products aimed at various clinical applications, including chronic rhinosinusitis and disinfection of endotracheal tubes. The company focuses on providing environmentally safe, cost-effective solutions to combat the growing challenge of antimicrobial resistance.

• Employees 18
• Founded 1999
• Annual Revenue $1425000
• Total Funding $152043400